PriceTargets.com logo

Altimmune - ALT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 162.81%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$7.61 As of 11/15/2024 01:00 AM ET
▼ -0.84 (-9.94%)

This chart shows the closing price for ALT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Altimmune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALT

Analyst Price Target is $20.00
▲ +162.81% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $20.00, with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 162.81% upside from the last price of $7.61.

This chart shows the closing price for ALT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in Altimmune. This rating has held steady since February 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
11/12/2024UBS GroupInitiated CoverageBuy$26.00
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
8/12/2024B. RileyReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
8/9/2024Evercore ISIUpgradeStrong-Buy
6/25/2024B. RileyReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
6/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
5/10/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $24.00
4/29/2024GuggenheimDowngradeBuy ➝ Neutral
4/1/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $12.00
3/28/2024B. RileyReiterated RatingBuy ➝ Buy$20.00
2/13/2024B. RileyReiterated RatingBuy ➝ Buy$20.00
1/24/2024The Goldman Sachs GroupInitiated CoverageNeutral$13.00
12/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
11/9/2023B. RileyLower TargetBuy ➝ Buy$15.00 ➝ $8.00
8/14/2023HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $15.00
8/11/2023B. RileyLower TargetBuy ➝ Buy$20.00 ➝ $15.00
3/31/2023JMP SecuritiesReiterated RatingMarket Outperform$15.00
3/22/2023JMP SecuritiesReiterated RatingMarket Outperform$26.00
3/21/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$20.00 ➝ $6.00
3/9/2023HC WainwrightReiterated RatingBuy$50.00
1/20/2023HC WainwrightReiterated RatingBuy$50.00
1/18/2023Evercore ISIBoost TargetOutperform$14.00 ➝ $25.00
12/1/2022The Goldman Sachs GroupInitiated CoverageBuy$20.00
11/11/2022JMP SecuritiesLower TargetMarket Outperform$28.00 ➝ $26.00
9/16/2022GuggenheimLower TargetBuy$31.00 ➝ $26.00
8/31/2022Jefferies Financial GroupBoost TargetBuy$30.00 ➝ $35.00
8/17/2022HC WainwrightBoost TargetBuy$25.00 ➝ $50.00
8/12/2022B. RileyBoost TargetBuy$21.00 ➝ $26.00
7/5/2022HC WainwrightReiterated RatingBuy$25.00
6/1/2022JMP SecuritiesReiterated RatingBuy$22.00
5/17/2022Piper SandlerLower TargetOverweight$34.00 ➝ $25.00
5/17/2022HC WainwrightReiterated RatingBuy$25.00
5/16/2022GuggenheimLower TargetNA$27.00
3/22/2022HC WainwrightReiterated RatingBuy$25.00
3/16/2022GuggenheimLower Target$33.00 ➝ $28.00
1/24/2022B. RileyLower Target$27.00 ➝ $21.00
12/30/2021Jefferies Financial GroupInitiated CoverageBuy$30.00
9/28/2021JMP SecuritiesReiterated RatingBuy$31.00
9/8/2021Piper SandlerBoost TargetOverweight$16.00 ➝ $34.00
9/7/2021B. RileyBoost TargetBuy$21.00 ➝ $27.00
8/30/2021HC WainwrightReiterated RatingBuy$25.00
8/12/2021Jefferies Financial GroupBoost TargetIn-Line ➝ Buy$14.00 ➝ $30.00
7/1/2021Evercore ISIReiterated RatingBuy$25.00
6/30/2021B. RileyLower TargetBuy$41.00 ➝ $21.00
6/30/2021GuggenheimLower TargetBuy$52.00 ➝ $42.00
6/30/2021HC WainwrightLower TargetBuy$35.00 ➝ $25.00
6/30/2021JMP SecuritiesLower TargetOutperform$53.00 ➝ $31.00
6/16/2021JMP SecuritiesBoost TargetMarket Outperform$45.00 ➝ $53.00
6/16/2021HC WainwrightReiterated RatingBuy$35.00
6/2/2021HC WainwrightInitiated CoverageBuy$35.00
2/18/2021B. RileyBoost TargetBuy$28.00 ➝ $41.00
2/10/2021GuggenheimInitiated CoverageBuy$36.00 ➝ $36.00
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$25.00
11/24/2020Evercore ISIReiterated RatingOutperform$25.00
11/12/2020B. RileyLower TargetBuy$31.00 ➝ $28.00
10/13/2020B. RileyReiterated RatingBuy$31.00
9/25/2020B. RileyInitiated CoverageBuy$31.00
9/24/2020B. RileyReiterated RatingBuy
8/14/2020Evercore ISIInitiated CoverageOutperform
7/30/2020Piper SandlerInitiated CoverageOverweight
7/28/2020JMP SecuritiesInitiated CoverageOutperform
2/24/2020Roth CapitalInitiated CoverageBuy$13.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
Mentions as of
4/21/2024
  • 18 very positive mentions
  • 47 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
5/21/2024
  • 9 very positive mentions
  • 56 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 11 very positive mentions
  • 52 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 8 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 9 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 6 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 10 very positive mentions
  • 32 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 10 very positive mentions
  • 32 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Altimmune logo
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $7.61
Low: $7.46
High: $8.54

50 Day Range

MA: $7.02
Low: $6.02
High: $9.52

52 Week Range

Now: $7.61
Low: $2.34
High: $14.84

Volume

5,412,739 shs

Average Volume

3,532,536 shs

Market Capitalization

$541.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Altimmune?

The following Wall Street research analysts have issued reports on Altimmune in the last year: B. Riley, Evercore ISI, Guggenheim, HC Wainwright, JMP Securities, Piper Sandler, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for ALT.

What is the current price target for Altimmune?

0 Wall Street analysts have set twelve-month price targets for Altimmune in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 162.8%. UBS Group AG has the highest price target set, predicting ALT will reach $26.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Altimmune in the next year.
View the latest price targets for ALT.

What is the current consensus analyst rating for Altimmune?

Altimmune currently has 2 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALT.

What other companies compete with Altimmune?

Other companies that are similar to Altimmune include Arbutus Biopharma, Kamada, Fulcrum Therapeutics, CTI BioPharma and BeyondSpring. Learn More about companies similar to Altimmune.

How do I contact Altimmune's investor relations team?

Altimmune's physical mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The company's listed phone number is (240) 654-1450 and its investor relations email address is [email protected]. The official website for Altimmune is altimmune.com. Learn More about contacing Altimmune investor relations.